{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:35:58Z","timestamp":1773880558354,"version":"3.50.1"},"reference-count":49,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bisphosphonates (BPs) are potent inhibitors of osteoclast mediated bone resorption. These drugs are widely used in the management of osteoporosis and other diseases, characterized by high bone turnover. The effect of BPs on gestation and lactation, when they are used as therapeutic agents in premenopausal women, is yet unknown. We conducted a detailed literature review and identified the cases of BPs use in young women, as well as, the effects of this therapy on the gestation and the embryo. The published data, regarding the use of BPs in premenopausal women and their effects on the pregnancy outcome, are limited. However, we could identify the outcomes of 40 pregnant women, who had received BPs prior to or during pregnancy, that have been documented in the literature. All women had valid indications to receive BPs for serious bone metabolism conditions. We could not identify any prospective trials, which focus on pregnancy outcomes following after the\n                    <jats:italic>in-utero<\/jats:italic>\n                    exposure to BPs. In total, no serious adverse effects were reported. Problems related to the offspring, such as hypocalcemia and a tendency for low body weight (LBW), were self-resolving. In addition, no serious adverse outcomes were reported for women having completed pregnancy. Nevertheless, follow-up was limited for both outcomes suggesting the necessity of national and international registries.\n                  <\/jats:p>","DOI":"10.1515\/hmbci-2019-0021","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T05:02:46Z","timestamp":1568955766000},"source":"Crossref","is-referenced-by-count":11,"title":["Clinical evidence of the effect of bisphosphonates on pregnancy and the infant"],"prefix":"10.1515","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2260-9709","authenticated-orcid":false,"given":"Nikolaos","family":"Machairiotis","sequence":"first","affiliation":[{"name":"Obstetric Gynecology Department , Royal Oldham Hospital, The Pennine Acute Hospitals Trust , Oldham , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Ntali","sequence":"additional","affiliation":[{"name":"Department of Endocrinology-Diabetes , Evangelismos Hospital , Athens , Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paraskevi","family":"Kouroutou","sequence":"additional","affiliation":[{"name":"MITERA PRIVATE HOSPITAL , 3rd INTERNAL MEDICINE CLINIC , ATHENS , Greece"},{"name":"Internal Medicine Department , \u201cThriassio\u201d General Hospital , Athens , Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Michala","sequence":"additional","affiliation":[{"name":"First Department of Obstetrics Gynecology , Alexandra Hospital, National and Kapodistrian University of Athens , Athens , Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,9,20]]},"reference":[{"key":"2025121207191539016_j_hmbci-2019-0021_ref_001_w2aab3b7b2b1b6b1ab1b6b1Aa","doi-asserted-by":"crossref","unstructured":"Henneman ZJ, Nancollas GH, Ebetino FH, Russell RG, Phipps RJ. Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res B. 2008;85A:993\u20131000.10.1002\/jbm.a.31599","DOI":"10.1002\/jbm.a.31599"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_002_w2aab3b7b2b1b6b1ab1b6b2Aa","doi-asserted-by":"crossref","unstructured":"Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol. 2006;6:307\u201312.10.1016\/j.coph.2006.03.00516650801","DOI":"10.1016\/j.coph.2006.03.005"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_003_w2aab3b7b2b1b6b1ab1b6b3Aa","doi-asserted-by":"crossref","unstructured":"Rogers MJ, Crockett JC, Coxon FP, Monkkonen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011;49:34\u201341.2111185310.1016\/j.bone.2010.11.008","DOI":"10.1016\/j.bone.2010.11.008"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_004_w2aab3b7b2b1b6b1ab1b6b4Aa","doi-asserted-by":"crossref","unstructured":"Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem. 1999;274:34967\u201373.10.1074\/jbc.274.49.3496710574973","DOI":"10.1074\/jbc.274.49.34967"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_005_w2aab3b7b2b1b6b1ab1b6b5Aa","doi-asserted-by":"crossref","unstructured":"Gong L, Altman RB, Klein TE. Bisphosphonates pathway. Pharmacogenet Genomics. 2011;21:50\u20133.2002359410.1097\/FPC.0b013e328335729c","DOI":"10.1097\/FPC.0b013e328335729c"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_006_w2aab3b7b2b1b6b1ab1b6b6Aa","doi-asserted-by":"crossref","unstructured":"Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209\u201357.10.1196\/annals.1402.08918056045","DOI":"10.1196\/annals.1402.089"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_007_w2aab3b7b2b1b6b1ab1b6b7Aa","doi-asserted-by":"crossref","unstructured":"Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006;1068:367\u2013401.1683193810.1196\/annals.1346.041","DOI":"10.1196\/annals.1346.041"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_008_w2aab3b7b2b1b6b1ab1b6b8Aa","doi-asserted-by":"crossref","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733\u201359.10.1007\/s00198-007-0540-818214569","DOI":"10.1007\/s00198-007-0540-8"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_009_w2aab3b7b2b1b6b1ab1b6b9Aa","doi-asserted-by":"crossref","unstructured":"Hirschberg R. Renal complications from bisphosphonate treatment. Curr Opin Support Palliat Care. 2012;6:342\u20137.10.1097\/SPC.0b013e328356062e22710581","DOI":"10.1097\/SPC.0b013e328356062e"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_010_w2aab3b7b2b1b6b1ab1b6c10Aa","doi-asserted-by":"crossref","unstructured":"O\u2019Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474.29082518","DOI":"10.1002\/14651858.CD003474.pub4"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_011_w2aab3b7b2b1b6b1ab1b6c11Aa","doi-asserted-by":"crossref","unstructured":"Lopez-Olivo MA, Shah NA, Pratt G, Risser JM, Symanski E, Suarez-Almazor ME. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer. 2012;20:2985\u201398.10.1007\/s00520-012-1563-z22956190","DOI":"10.1007\/s00520-012-1563-z"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_012_w2aab3b7b2b1b6b1ab1b6c12Aa","doi-asserted-by":"crossref","unstructured":"Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. 2012;16:CD003188.","DOI":"10.1002\/14651858.CD003188.pub3"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_013_w2aab3b7b2b1b6b1ab1b6c13Aa","doi-asserted-by":"crossref","unstructured":"Ben-Aharon I, Vidal L, Rizel S, Yerushalmi R, Shpilberg O, Sulkes A, et al. Bisphosphonates in the adjuvant setting of breast cancer therapy \u2013 effect on survival: a systematic review and meta-analysis. PLoS One. 2013;8:e70044.23990894","DOI":"10.1371\/journal.pone.0070044"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_014_w2aab3b7b2b1b6b1ab1b6c14Aa","doi-asserted-by":"crossref","unstructured":"Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16(Suppl 3):1\u201337.","DOI":"10.4158\/EP.16.S3.1"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_015_w2aab3b7b2b1b6b1ab1b6c15Aa","doi-asserted-by":"crossref","unstructured":"Carbone EJ, Rajpura K, Allen BN, Cheng E, Ulery BD, Lo KW. Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties. Nanomedicine. 2017;13:37\u201347.2756221110.1016\/j.nano.2016.08.015","DOI":"10.1016\/j.nano.2016.08.015"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_016_w2aab3b7b2b1b6b1ab1b6c16Aa","doi-asserted-by":"crossref","unstructured":"Dang L, Liu J, Li F, Wang L, Li D, Guo B, et al. Targeted delivery systems for molecular therapy in skeletal disorders. Int J Mol Sci. 2016;17(3):428.10.3390\/ijms1703042827011176","DOI":"10.3390\/ijms17030428"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_017_w2aab3b7b2b1b6b1ab1b6c17Aa","doi-asserted-by":"crossref","unstructured":"Coxon F, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol. 2006;6(3):307\u201312.10.1016\/j.coph.2006.03.00516650801","DOI":"10.1016\/j.coph.2006.03.005"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_018_w2aab3b7b2b1b6b1ab1b6c18Aa","doi-asserted-by":"crossref","unstructured":"Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2\u201319.2155500310.1016\/j.bone.2011.04.022","DOI":"10.1016\/j.bone.2011.04.022"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_019_w2aab3b7b2b1b6b1ab1b6c19Aa","doi-asserted-by":"crossref","unstructured":"Van Breukelen FJ, Bijvoet OM, Van Oosterom AT. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (A.P.D.). Prelim Commun. 1979;313:P803\u20135.","DOI":"10.1016\/S0140-6736(79)91319-9"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_020_w2aab3b7b2b1b6b1ab1b6c20Aa","doi-asserted-by":"crossref","unstructured":"Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323:73\u20139.211361110.1056\/NEJM199007123230201","DOI":"10.1056\/NEJM199007123230201"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_021_w2aab3b7b2b1b6b1ab1b6c21Aa","doi-asserted-by":"crossref","unstructured":"Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189\u201399.1502882310.1056\/NEJMoa030897","DOI":"10.1056\/NEJMoa030897"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_022_w2aab3b7b2b1b6b1ab1b6c22Aa","doi-asserted-by":"crossref","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809\u201322.1747600710.1056\/NEJMoa067312","DOI":"10.1056\/NEJMoa067312"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_023_w2aab3b7b2b1b6b1ab1b6c23Aa","doi-asserted-by":"crossref","unstructured":"Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone. 2011;49:42\u20139.10.1016\/j.bone.2011.01.01421281748","DOI":"10.1016\/j.bone.2011.01.014"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_024_w2aab3b7b2b1b6b1ab1b6c24Aa","doi-asserted-by":"crossref","unstructured":"Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone. 2011;49:103\u201310.10.1016\/j.bone.2011.01.00321236370","DOI":"10.1016\/j.bone.2011.01.003"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_025_w2aab3b7b2b1b6b1ab1b6c25Aa","doi-asserted-by":"crossref","unstructured":"Dunlop DJ, Soukop M, McEwan HP. Antenatal administration of aminopropylidene diphosphonate. Ann Rheumatic Dis. 1990;49:955.10.1136\/ard.49.11.955-a","DOI":"10.1136\/ard.49.11.955-a"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_026_w2aab3b7b2b1b6b1ab1b6c26Aa","doi-asserted-by":"crossref","unstructured":"Rutgers-Verhage AR, deVries TW, Torringa MJ. No effects of bisphosphonates on the human fetus. Birth Defects Res A Clin Mol Teratol. 2003;67:203\u20134.1279746310.1002\/bdra.10016","DOI":"10.1002\/bdra.10016"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_027_w2aab3b7b2b1b6b1ab1b6c27Aa","doi-asserted-by":"crossref","unstructured":"Chen CP, Lin SP, Su YN, Huang JP, Chern SR, Su JW, et al. Uncomplicated vaginal delivery in two consecutive pregnancies carried to term in a woman with osteogenesis imperfecta type I and bisphosphonate treatment before conception. Taiwan J Obstet Gynecol. 2012;51:305\u20137.10.1016\/j.tjog.2012.04.029","DOI":"10.1016\/j.tjog.2012.04.029"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_028_w2aab3b7b2b1b6b1ab1b6c28Aa","doi-asserted-by":"crossref","unstructured":"Biswas PN, Wilton LV, Shakir SA. Pharmacovigilance study of alendronate in England. Osteoporos Int. 2003;14:507\u201314.10.1007\/s00198-003-1399-y12730757","DOI":"10.1007\/s00198-003-1399-y"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_029_w2aab3b7b2b1b6b1ab1b6c29Aa","doi-asserted-by":"crossref","unstructured":"Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol. 2006;22:578\u20139.1699624510.1016\/j.reprotox.2006.05.009","DOI":"10.1016\/j.reprotox.2006.05.009"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_030_w2aab3b7b2b1b6b1ab1b6c30Aa","doi-asserted-by":"crossref","unstructured":"Hassen-Zrour S, Korbaa W, Bejia I, Saidani Z, Bergaoui N. Maternal and fetal outcome after long-term bisphosphonate exposure before conception. Osteoporos Int. 2010;21:709\u201310.10.1007\/s00198-009-0983-119533208","DOI":"10.1007\/s00198-009-0983-1"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_031_w2aab3b7b2b1b6b1ab1b6c31Aa","doi-asserted-by":"crossref","unstructured":"Chan B, Zacharin M. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab. 2006;91:2017\u201320.10.1210\/jc.2005-2548","DOI":"10.1210\/jc.2005-2548"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_032_w2aab3b7b2b1b6b1ab1b6c32Aa","doi-asserted-by":"crossref","unstructured":"Vujasinovic-Stupar N, Pejnovic N, Markovic L, Zlatanovic M. Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome. Rheumatol Int. 2012;32:819\u201323.2132742910.1007\/s00296-011-1816-z","DOI":"10.1007\/s00296-011-1816-z"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_033_w2aab3b7b2b1b6b1ab1b6c33Aa","doi-asserted-by":"crossref","unstructured":"Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone. 2009;44:428\u201330.1905937010.1016\/j.bone.2008.11.001","DOI":"10.1016\/j.bone.2008.11.001"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_034_w2aab3b7b2b1b6b1ab1b6c34Aa","doi-asserted-by":"crossref","unstructured":"Mastaglia SR, Watman NP, Oliveri B. Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health. Osteoporos Int. 2010;21:1959\u201362.10.1007\/s00198-009-1138-020535608","DOI":"10.1007\/s00198-009-1138-0"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_035_w2aab3b7b2b1b6b1ab1b6c35Aa","doi-asserted-by":"crossref","unstructured":"Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res. 2004;19:1742\u20135.10.1359\/JBMR.040711","DOI":"10.1359\/JBMR.040711"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_036_w2aab3b7b2b1b6b1ab1b6c36Aa","unstructured":"Cabar FR, Nomura RM, Zugaib M. Maternal and fetal outcome of pamidronate treatment before conception: a case report. Clin Exp Rheumatol. 2007;25:344\u20135."},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_037_w2aab3b7b2b1b6b1ab1b6c37Aa","doi-asserted-by":"crossref","unstructured":"Culbert EC, Schfirin BS. Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions. Obstet Gynecol. 2006;108:789\u201391.1701850410.1097\/01.AOG.0000209183.39581.e9","DOI":"10.1097\/01.AOG.0000209183.39581.e9"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_038_w2aab3b7b2b1b6b1ab1b6c38Aa","doi-asserted-by":"crossref","unstructured":"Illidge TM, Hussey M, Godden CW. Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol. 1996;8:257\u20138.10.1016\/S0936-6555(05)80667-3","DOI":"10.1016\/S0936-6555(05)80667-3"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_039_w2aab3b7b2b1b6b1ab1b6c39Aa","doi-asserted-by":"crossref","unstructured":"Athimulam S, Chan P, Baker M, Nauta M, Yoong W. The effect of pregnancy on pre-existing osteopenia: a case report. Arch Gynecol Obstet. 2007;276:175\u20137.10.1007\/s00404-007-0321-917287982","DOI":"10.1007\/s00404-007-0321-9"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_040_w2aab3b7b2b1b6b1ab1b6c40Aa","doi-asserted-by":"crossref","unstructured":"Gerin M, Jambon G, Fouque-Aubert A, Raybaud C, Cochat P, Claris O, et al. Neonatal transient hypophosphatemic hypercalciuric rickets in dizygous twins: a role for maternal alendronate therapy before pregnancy or antireflux medications? Arch Pediatr. 2016;23:957\u201362.10.1016\/j.arcped.2016.03.00127150561","DOI":"10.1016\/j.arcped.2016.03.001"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_041_w2aab3b7b2b1b6b1ab1b6c41Aa","doi-asserted-by":"crossref","unstructured":"Andreadis C, Charalampidou M, Diamantopoulos N, Chouchos N, Mouratidou D. Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer. Gynecol Oncol. 2004;95:252\u20135.10.1016\/j.ygyno.2004.06.037","DOI":"10.1016\/j.ygyno.2004.06.037"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_042_w2aab3b7b2b1b6b1ab1b6c42Aa","doi-asserted-by":"crossref","unstructured":"Green SB, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. Am J Health Syst Pharm. 2014;71:2029\u201336.10.2146\/ajhp14004125404594","DOI":"10.2146\/ajhp140041"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_043_w2aab3b7b2b1b6b1ab1b6c43Aa","doi-asserted-by":"crossref","unstructured":"Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60:68\u201373.10.1002\/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H10440778","DOI":"10.1002\/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.3.CO;2-8"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_044_w2aab3b7b2b1b6b1ab1b6c44Aa","unstructured":"Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011."},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_045_w2aab3b7b2b1b6b1ab1b6c45Aa","doi-asserted-by":"crossref","unstructured":"Stathopoulos IP, Liakou CG, Katsalira A, Trovas G, Lyritis GG, Papaioannou NA, et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones. 2011;10:280\u201391.10.14310\/horm.2002.131922281884","DOI":"10.14310\/horm.2002.1319"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_046_w2aab3b7b2b1b6b1ab1b6c46Aa","doi-asserted-by":"crossref","unstructured":"Losada I, Sartori L, Di Gianantonio E, Zen M, Clementi M, Doria A. Bisphosphonates in patients with autoimmune rheumatic diseases: can they be used in women of childbearing age? Autoimmun Rev. 2010;9:547\u201352.10.1016\/j.autrev.2010.03.00220307690","DOI":"10.1016\/j.autrev.2010.03.002"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_047_w2aab3b7b2b1b6b1ab1b6c47Aa","doi-asserted-by":"crossref","unstructured":"Siminoski K, Fitzgerald AA, Flesch G, Gross MS. Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res. 2000;15:2052\u20135.10.1359\/jbmr.2000.15.10.205211028460","DOI":"10.1359\/jbmr.2000.15.10.2052"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_048_w2aab3b7b2b1b6b1ab1b6c48Aa","doi-asserted-by":"crossref","unstructured":"Peris P, Torra M, Olivares V, Reyes R, Monegal A, Martinez-Ferrer A, et al. Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone. 2011;49:706\u20139.10.1016\/j.bone.2011.06.02721742070","DOI":"10.1016\/j.bone.2011.06.027"},{"key":"2025121207191539016_j_hmbci-2019-0021_ref_049_w2aab3b7b2b1b6b1ab1b6c49Aa","doi-asserted-by":"crossref","unstructured":"Reid IR, Wattie DJ, Evans MC, Budayr AA. Post-pregnancy osteoporosis associated with hypercalcaemia. Clin Endocrinol. 1992;37:298\u2013303.10.1111\/j.1365-2265.1992.tb02325.x","DOI":"10.1111\/j.1365-2265.1992.tb02325.x"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/hmbci.2019.40.issue-2\/hmbci-2019-0021\/hmbci-2019-0021.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0021\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0021\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:09:54Z","timestamp":1765526994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0021\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,20]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,10,11]]},"published-print":{"date-parts":[[2019,11,26]]}},"alternative-id":["10.1515\/hmbci-2019-0021"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2019-0021","relation":{},"ISSN":["1868-1891","1868-1883"],"issn-type":[{"value":"1868-1891","type":"electronic"},{"value":"1868-1883","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,20]]},"article-number":"20190021"}}